Rodriguez CP, et al. - As a part of this trial, authors contemplated the microtubule inhibitor eribulin in recurrent/metastatic salivary gland cancers (RMSGCs), a disease where no therapeutic standard existed. Findings disclosed that the objective responses to eribulin were uncommon. Nonetheless, disease control was noted in maximum patients.